BAK Downgraded by HSBC -- Price Target Lowered to $1.50

HSBC downgraded Braskem (BAK) from Buy to Hold, lowering its price target from $6.50 to $1.50. GuruFocus values BAK at $5.14, suggesting a 70% undervaluation at its current price of $1.54. The company's GF Score is 53/100, indicating mixed financial performance.

Original reporting
Published Sep 28, 2026, 11:02 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$BAK
Bearish
high confidence
Mentioned
$BAK
Relevance
6/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$BAKBearishMed
01

Why it matters

HSBC’s downgrade and target cut could trigger short‑term selling, but value metrics may attract contrarian investors.

02

Market read

The downgrade provides fresh, material information for traders holding or watching BAK, with potential spill‑over to the chemical sector.

03

What to watch

Insider activity shows no recent sales, and the company’s cash‑flow issues may be temporary if commodity prices rebound.

Relevance 6/10Novelty 6/10Timing: today

Background

Braskem (BAK) is a Brazilian petrochemical producer with recent financial struggles, negative cash flow, and a low P/S ratio.

Company-level read

Ticker impact

$BAKBearishHigh confidence
Context

HSBC downgraded Braskem from Buy to Hold and cut the price target to $1.50, a fresh analyst action that can move the stock.

Expected impact

likely pressure as the market prices in the lower target and reduced rating

Evidence & confidence

Analyst downgrades with a 76% target reduction historically trigger short-term sell-offs, especially for a low‑priced, financially stressed stock.

Market effects

May weigh on other petrochemical and chemical stocks as analysts reassess valuation multiples.

Potentially drags Brazil‑focused equities and emerging‑market chemical exporters.

Limited to investors with exposure to Braskem or the broader chemical sector.

Counterpoint

The GF Value suggests the stock is still deeply undervalued, offering a contrarian buying opportunity despite the downgrade.

Key entities

  • HSBC

    Downgraded Braskem from Buy to Hold and cut price target to $1.50.

  • Braskem SA

    Brazilian petrochemical company, ticker BAK.

Related articles

$BAKMed

Carlos Slim Helu Discloses 6.5% Stake in BRASKEM SA

Carlos Slim Helu and related parties disclosed a 6.5% stake in BRASKEM SA's Class A preferred shares, according to a November 6, 2026, Schedule 13D filing. The group, which includes family members and foundations, acquired the shares for investment purposes and has no current plans to influence the company's control or operations. They may discuss the company with management or propose changes in the future.

Med

Braskem Creditors Ask Owners for US$1.85B

Braskem's creditors extended the restructuring deadline to 30 October 2026 and requested a US$1.85 billion capital commitment from shareholders, proposing a US$1.85 billion debt-to-equity swap. Braskem offered a US$1.7 billion capital injection in installments. The restructuring covers US$10.9 billion of debt, with a US court receiving a Chapter 11 petition against Braskem's US finance unit.

$BAKMedAI 8/10

Braskem nearing debt restructuring agreement

Braskem and its creditors are nearing a debt restructuring agreement for $11 billion. Both parties propose an equity offering with capital injections and a debt-to-equity swap, with amounts differing between $4 billion and $5 billion. This is the closest the two sides have been to a deal during out-of-court restructuring talks, according to sources.

MedAI 8/10

Braskem creditors, shareholders near deal on $11bn debt restructuring - Bloomberg

Braskem (BVMF) and creditors are close to a $11bn debt restructuring deal, with proposals involving equity injections and debt-to-equity conversions. Creditors' plan includes $4bn in initial capital, while Braskem's proposal totals $5bn. Both sides have until November 22 to finalize the agreement, with Petrobras (NYSE:PBR) and IG4 Capital Group retaining control under Braskem's plan.

$BAKMed

Braskem Unit Faces US Chapter 11 Petition

Three funds holding US$272 million of Braskem America Finance's bonds filed an involuntary Chapter 11 petition in New York. Braskem states only the finance unit is affected, not the parent company. The 2041 notes are guaranteed by Braskem S.A., which is negotiating debt restructuring in Brazil.